Shield Therapeutics ( http://www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield is currently conducting pivotal Phase 3 studies of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.
About IDA and the CKD Therapeutics Market
Epidemiology data suggests the current total IDA patient population in the EU, USA and Japan is approximately 34m, with an addressable population of 2.6m (IBD and CKD in the EU and US) in the first instance. The company estimates that the core market in IDA is worth at least $3.0bn. In addition, the global CKD therapeutics market is forecast to grow at a compound annual growth rate (CAGR) of 6.4% to reach $11.6billion by 2018 [ 1 ].
[ 1 ]Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018, GlobalData, September 2011For more information about Shield Therapeutics, please contact: Consilium Strategic Communications Mary-Jane Elliott / Emma Thompson / Lindsey Neville Tel +44(0)20-7920-2333 Email: email@example.com SOURCE Shield Therapeutics